Best Lynch-Style Stocks in Biotechnology for 2026
Growth at a reasonable price (GARP): strong growth with reasonable valuations.
Biotechnology spans the cash-generative commercial-stage companies and the pre-revenue clinical-stage cohort. Composite scoring is harsh on cash-burning names via the Health pillar (runway, cash to market cap); commercial-stage biotechs surface through the Quality pillar (gross margin, ROIC) and Valuation pillar.
Data as of (updated daily)
Top 20 Biotechnology stocks by growth score
| # | Ticker | Name | Growth |
|---|---|---|---|
| 1 | 002653.SHE | Xizang Haisco Pharmaceutical Group Co Ltd | 96.0 |
| 2 | 005690.KO | Pharmicell | 95.1 |
| 3 | 068270.KO | Celltrion Inc | 85.7 |
| 4 | ARGX.US | argenx NV ADR | 81.6 |
| 5 | PLX.US | Protalix Biotherapeutics Inc | 78.8 |
| 6 | PRTA.US | Prothena Corporation plc | 77.4 |
| 7 | ARWR.US | Arrowhead Pharmaceuticals Inc | 76.4 |
| 8 | INSM.US | Insmed Inc | 75.2 |
| 9 | DXB.AU | Dimerix Ltd | 74.7 |
| 10 | 2269.HK | WuXi Biologics | 73.6 |
| 11 | CYTK.US | Cytokinetics Inc | 72.7 |
| 12 | AUPH.US | Aurinia Pharmaceuticals Inc | 72.4 |
| 13 | ICCC.US | ImmuCell Corporation | 71.9 |
| 14 | IMM.AU | Immutep Ltd | 69.8 |
| 15 | DARE.US | Dare Bioscience Inc | 69.0 |
| 16 | RIGL.US | Rigel Pharmaceuticals Inc | 68.7 |
| 17 | CRMD.US | CorMedix Inc | 68.0 |
| 18 | VCEL.US | Vericel Corp Ord | 67.8 |
| 19 | PYC.LSE | Physiomics Plc | 67.2 |
| 20 | A1RG34.SA | argenx SE | 66.6 |
Customise the Lynch-Style Stocks + Biotechnology screen
The full screener applies both filters and lets you stack 30+ more on top: market cap, country, dividend yield, and the four pillar scores.
Open in screener →Explore related pages
Lynch-Style Stocks in other industries
Other strategies in Biotechnology
Browse the hub pages
Methodology: How we score stocks. Data refreshed nightly around 03:30 ET. This page lists the top 20 by growth score within the Biotechnology industry; use the screener for the full ranked list.